AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial

Autor:	Elena A Smolyarchuk, Natalia V. Vostokova, Andrew A. Blinow, Elena V Yakubova, Ruben N. Karapetian, Elena G. Tikhomolova, Nikolay Filippovich Savchuk, Tagir A. Sitdekov, Elena A. Merkulova, Kirill A. Dmitriev, Elena N Simakina, Elena P. Pavlikova, Valeria N Azarova, Natalia A. Papazova, Andrey Alexandrovich Ivashchenko, Alexandre V. Ivachtchenko, Alina N. Egorova, Nikita V. Lomakin, Dmitry V. Kravchenko, Alexey P. Ilin, Ivan G. Gordeev
Jazyk:	angličtina
Rok vydání:	2020
Předmět:	0301 basic medicine Microbiology (medical) medicine.medical_specialty Coronavirus disease 2019 (COVID-19) 030106 microbiology favipiravir Favipiravir Marketing authorization Antiviral Agents law.invention 03 medical and health sciences 0302 clinical medicine Randomized controlled trial law Internal medicine Interim medicine Humans 030212 general & internal medicine Stage (cooking) SARS-CoV-2 business.industry Brief Report COVID-19 Clinical trial AcademicSubjects/MED00290 Treatment Outcome Infectious Diseases RNA Polymerase Inhibitor AVIFAVIR Drug Therapy Combination business
Zdroj:	Clinical Infectious Diseases Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
ISSN:	1537-6591 1058-4838
DOI:	10.1093/cid/ciaa1176
Popis:	In May 2020 the Russian Ministry of Health granted fast-track marketing authorization to RNA polymerase inhibitor AVIFAVIR (favipiravir) for the treatment of COVID-19 patients. In the pilot stage of Phase II/III clinical trial, AVIFAVIR enabled SARS-CoV-2 viral clearance in 62.5% of patients within 4 days, and was safe and well-tolerated. Clinical Trials Registration. NCT04434248.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4109742bd2d16e1c3759cb50b641d0e5 Zobrazit plný text záznamu